PunditScore
Pundits › Joseph Stringer
JS

Joseph Stringer

Compare →
Senior Analyst, Needham & Company
Financial & Wall StreetBiotechnology

Joseph Stringer, Ph.D. is a Senior Analyst at Needham & Company, specializing in biotechnology. He joined Needham in 2017 after working as a research scientist at Ra Pharmaceuticals and completing postdoctoral research at Yale University.

Score over time

The PunditScore after each graded call, on the panel's score bands.
Well above cohortAbove cohortAt cohort averageBelow cohortWell below cohort0102030405060708090100#1#3#5#7Panel average per prediction — 56.3RIGHT2021-08-05 — Sign in to read this call.2024-05-07 — Sign in to read this call.2024-05-07 — Sign in to read this call.2026-02-13 — Sign in to read this call.2026-02-13 — Sign in to read this call.PARTLY2024-05-07 — Sign in to read this call.WRONG2021-04-28 — Sign in to read this call.2025-10 — Sign in to read this call.OPEN2026-01-07 — Sign in to read this call.2026-03 — Sign in to read this call.2026-04 — Sign in to read this call.2026-04 — Sign in to read this call.2026-05-15 — Sign in to read this call.2026-05-15 — Pelacarsen will generate about $2.7 billion in peak, non-risk-adjusted sales, translating into roughly $615 million in peak royalty revenue for Ionis.2026-05-15 — Sign in to read this call.2026-07-29 — Joseph Stringer predicts Ionis Pharmaceuticals will reach a price of $86.00, indicating a 42.67% upside.2026-07-30 — Joseph Stringer predicts Alnylam Pharma will reach a price of $357.00, indicating a 47.39% upside.2026-08 — Gilead Sciences Inc will reach a price of $170.00.2026-08 — Bioage Labs Inc will reach a price of $35.00.2026-08 — Annexon Inc will reach a price of $25.00.2026-09 — Vaxcyte Inc will reach a price of $110.00.2026-09 — Inflarx Nv will reach a price of $8.00.2026-09 — Ionis Pharmaceuticals Inc will reach a price of $86.00.2026-10 — Ionis Pharmaceuticals will bolster future earnings due to lucrative licensing deals with Ono and Sobi.
Hover a point to read the call. Click to pin it.
AXIS

Still open · 16

THE FRONT EDGE

Not resolved, so they don’t move the score.

?
Sign in to read this call.
Due Dec 31, 2026Said January 7, 2026BiotechVaccine
No market prices this claim
?
Sign in to read this call.
Due Mar 31, 2027 (12 months assumed)Said March 2026BiotechnologyPharmaceuticals
No market prices this claim
?
Sign in to read this call.
Due Apr 30, 2027 (12 months assumed)Said April 2026BiotechnologyPharmaceuticals
No market prices this claim
?
Sign in to read this call.
Due Apr 30, 2027 (12 months assumed)Said April 2026BiotechnologyPharmaceuticals
No market prices this claim
?
Sign in to read this call.
Due May 15, 2027 (12 months assumed)Said May 15, 2026BiotechPharmaceuticals
No market prices this claim
?
Joseph Stringer predicts Ionis Pharmaceuticals will reach a price of $86.00, indicating a 42.67% upside.
Due Jul 29, 2027 (12 months assumed)Said July 29, 2026PharmaceuticalsIonis
No market prices this claim
?
Joseph Stringer predicts Alnylam Pharma will reach a price of $357.00, indicating a 47.39% upside.
Due Jul 30, 2027 (12 months assumed)Said July 30, 2026PharmaceuticalsAlnylam
No market prices this claim
?
Annexon Inc will reach a price of $25.00.
Due Aug 1, 2027Said August 2026BiotechnologyPharmaceuticals
No market prices this claim
?
Vaxcyte Inc will reach a price of $110.00.
Due Aug 31, 2027Said September 2026BiotechnologyPharmaceuticals
No market prices this claim
?
Inflarx Nv will reach a price of $8.00.
Due Aug 31, 2027Said September 2026BiotechnologyPharmaceuticals
No market prices this claim
?
Gilead Sciences Inc will reach a price of $170.00.
Due Aug 31, 2027 (12 months assumed)Said August 2026BiotechnologyPharmaceuticals
No market prices this claim
?
Bioage Labs Inc will reach a price of $35.00.
Due Aug 31, 2027 (12 months assumed)Said August 2026BiotechnologyPharmaceuticals
No market prices this claim
?
Ionis Pharmaceuticals Inc will reach a price of $86.00.
Due Sep 30, 2027 (12 months assumed)Said September 2026BiotechnologyPharmaceuticals
No market prices this claim
?
Ionis Pharmaceuticals will bolster future earnings due to lucrative licensing deals with Ono and Sobi.
Said October 2026Healthcare
No market prices this claim
?
Sign in to read this call.
Said May 15, 2026BiotechPharmaceuticals
No market prices this claim
?
Pelacarsen will generate about $2.7 billion in peak, non-risk-adjusted sales, translating into roughly $615 million in peak royalty revenue for Ionis.
Said May 15, 2026BiotechPharmaceuticals
No market prices this claim